<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243424</url>
  </required_header>
  <id_info>
    <org_study_id>1218.74</org_study_id>
    <secondary_id>2009-013157-15</secondary_id>
    <nct_id>NCT01243424</nct_id>
  </id_info>
  <brief_title>CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the longterm impact on cardiovascular morbidity and
      mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight
      and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated
      cardiovascular risk receiving usual care, and compare outcome against glimepiride.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2010</start_date>
  <completion_date type="Actual">August 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The First 3-point Major Adverse Cardiovascular Events (3P−MACE)</measure>
    <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
    <description>The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The First 4-point (4P)− MACE</measure>
    <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
    <description>The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without &gt;2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase</measure>
    <time_frame>From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)</time_frame>
    <description>The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without &gt;2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without &gt;2% Weight Gain During Maintenance Phase</measure>
    <time_frame>From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)</time_frame>
    <description>The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without &gt;2% weight gain during maintenance phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE</measure>
    <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
    <description>Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE</measure>
    <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
    <description>Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events</measure>
    <time_frame>From start of the treatment until 7 days after the end of treatment, up to 433 weeks</time_frame>
    <description>Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:
CV death (including fatal stroke and fatal MI)
non-fatal MI
non-fatal stroke
hospitalisation for unstable angina pectoris
TIA
hospitalisation for heart failure
hospitalisation for coronary revascularisation procedures (CABG, PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events</measure>
    <time_frame>From start of the treatment until 7 days after the end of treatment, up to 433 weeks</time_frame>
    <description>Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:
CV death (including fatal stroke and fatal MI)
non-fatal MI
non-fatal stroke
hospitalisation for unstable angina pectoris
Transient ischaemic attack (TIA)
hospitalisation for heart failure
hospitalisation for coronary revascularisation procedures (CABG, PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Triglycerides</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Creatinine</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Transition in Albuminuria Classes</measure>
    <time_frame>Baseline and week 432</time_frame>
    <description>Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks</measure>
    <time_frame>Baseline and week 208</time_frame>
    <description>The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up</measure>
    <time_frame>433 weeks</time_frame>
    <description>Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6103</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepiride 1-4 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin</intervention_name>
    <description>linagliptin tablets 5mg QD</description>
    <arm_group_label>linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>glimepiride over-encapsulated tablet 1-4 mg QD</description>
    <arm_group_label>glimepiride 1-4 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin placebo</intervention_name>
    <description>linagliptin placebo</description>
    <arm_group_label>glimepiride 1-4 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride placebo</intervention_name>
    <description>glimepiride placebo</description>
    <arm_group_label>linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Type 2 diabetes

          2. Elevated glycosylated haemoglobin (HbA1c): 6.5 - 8.5%, inclusive, if treatment naïve
             or mono-/dual therapy with metformin and/or an alpha-glucosidase inhibitor; 6.5 -
             7.5%, inclusive, if treatment with sulphonylurea/glinide in mono- or dual (with
             metformin OR an alpha-glucosidase inhibitor) therapy)

          3. Pre-existing cardiovascular disease OR specified diabetes end-organ damage OR age =&gt;
             70 years OR two or more specified cardiovascular risk factor

          4. BMI =&lt; 45kg/m²

          5. age between &gt;= 40 and =&lt; 85 years

          6. signed and dated written International Conference of Harmonisation( ICF)

          7. stable anti-diabetic background for at least 8 wks before study start

        Exclusion criteria:

          1. Type 1 diabetes

          2. Treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone,
             Glucagon-like peptide 1 (GLP-1) analogue/agonists, Dipeptidyl-peptidase IV (DPP-IV)
             inhibitors or any insulin) prior to informed consent (previous short term use of
             insulin (up to two weeks) is allowed if taken at least 8 weeks prior informed consent)

          3. treatment with any anti-obesity drug less than 3 months before ICF

          4. uncontrolled hyperglycemia

          5. previous or planned bariatric surgery or intervention

          6. current or planned system corticoid treatment

          7. change in thyroid hormones treatment

          8. acute liver disease or impaired hepatic function

          9. pre-planned coronary artery revascularization within 6 months of ICF

         10. known hypersensitivity to any of the components

         11. Inappropriateness of glimepiride treatment for renal safety issues according to local
             prescribing information

         12. congestive heart failure class III or IV

         13. acute or chronic metabolic acidosis

         14. hereditary galactose intolerance

         15. alcohol or drug abuse

         16. participation in another trail with IMP given 2 months before Investigational
             Medicinal/Medical Product (IMP) start

         17. pre-menopausal women who are nursing or pregnant or of child-bearing potential and not
             willing to use acceptable method of birth control

         18. patients considered reliable by the investigator

         19. acute coronary syndrome =&lt; 6 wks before ICF

         20. stroke or Transient Ischemic Attack (TIA) =&lt; 3 months prior to ICF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Alabama Research Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Internal Medicine, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cahaba Research, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Center, LLC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Medical Clinic</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Extended Arm Physicians, Inc.</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Terence T. Hart MD</name>
      <address>
        <city>Tuscumbia</city>
        <state>Alabama</state>
        <zip>35674</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Pell City</city>
        <state>Alaska</state>
        <zip>35128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genova Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality of Life Medical &amp; Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Arkansas Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Investigations, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aureus Research, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Oasis Healthcare</name>
      <address>
        <city>Bermuda Dunes</city>
        <state>California</state>
        <zip>92203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinger Medical Group and Research Center</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of St. Jude Heritage Med. Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Center for Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Richard S. Cherlin</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaparral Medical Group, Inc</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARI Clinical Trials, Inc</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Sports Medicine and Family Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Research, LLC</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Institute of America</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matrix Research Institute</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Research</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Medical Associates</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Todd Kazdan, DO Family Practice</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Century Clinical Research, Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doral Research Center</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan Graff, MD, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M &amp; O Clinical Research, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research in Miami Inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Impotence Treatment Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Partners Clinical Research LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veritas Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APF Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Miami Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AppleMed Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall South Medical Center, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Research Center</name>
      <address>
        <city>Opa-locka</city>
        <state>Florida</state>
        <zip>33054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocrine Center of Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Misal Khan, MD FRCS, ED, PA</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iconic Clinical Trials</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Region Clinical Research Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Center for Clinical Research</name>
      <address>
        <city>Ponte Vedra Beach</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMI Health Research Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert F. Johary MD, PC</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research, LLC</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayden Lake Family Physicians</name>
      <address>
        <city>Hayden Lake</city>
        <state>Idaho</state>
        <zip>83835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boise Kidney and Hypertension Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Clinical Research</name>
      <address>
        <city>Bolingbrook</city>
        <state>Illinois</state>
        <zip>60490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger Jr. Hospital of Cook Country</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Medical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakon Inc</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigators Research Group, LLC</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <zip>46131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mapleton Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKinley Research, LLC</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCM Clinical Research, LLC</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Diabetes Endocrinology Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Four Rivers Clinical Research, Inc</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Clinical Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acadia Clinical Research, LLC</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Stephen R. Smith, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine and Metabolic Consultants</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tristan Medical Enterprises, PC dba Regeneris</name>
      <address>
        <city>North Attleboro</city>
        <state>Massachusetts</state>
        <zip>02760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSite, LLC</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Medical Research, AMR Inc</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center, PC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri City Medical Centers, PC</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMED Research</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-County Research, Inc</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Associates</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Medical Research Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Trials, Inc.</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Medical Research Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atco Medical Associates, PC</name>
      <address>
        <city>Atco</city>
        <state>New Jersey</state>
        <zip>08004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USMA Clinical Research</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Jersey Medical Research</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center / Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Associates of Long Island, PC</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southgate Medical Group/ Southgate Medical Park</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kernodle Clinic West</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaffney Health Services</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Internal Medicine Associates</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Family Medicine</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Research Center, Inc</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health Care of Manchester</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Associates, LLC</name>
      <address>
        <city>Austintown</city>
        <state>Ohio</state>
        <zip>44515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrison Community Research Center</name>
      <address>
        <city>Cadiz</city>
        <state>Ohio</state>
        <zip>43907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Frontiers, LLC</name>
      <address>
        <city>Carlisle</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genoa Medical Center</name>
      <address>
        <city>Genoa</city>
        <state>Ohio</state>
        <zip>43430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Craig S. Thompson, MD, LLC</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAS Health Limited</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research, LLC</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacotherapy Research Associates, Inc</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Research Group, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castlerock Clinical Research Consultants, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harleysville Medical Associates</name>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detweiler Family Medicine &amp; Associates, PC</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warminster Medical Associates, PC</name>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <zip>18974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research, Inc</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartwell Research Group, LLC</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris View Family Practice</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Nephrology and Hypertension Center, Inc</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Diabetes &amp; Kidney Center</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Diabetes and Endocrine Consultants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinical Research, LLC</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <zip>37388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRK Medical Research</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Punzi Medical Center</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacon Medical Research Associates, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JVC Family Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine and Psychiastry Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Clinical Research Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hill Country Medical Associates</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naidu Clinic</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital d/b/a HMRI CCAT at Pearland</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Health Partners</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research of San Antonio, LLC</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenneth Otah and Associates</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHS Clinical Trials</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <zip>84047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Internal Medicine and Research</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ettrick Health Center</name>
      <address>
        <city>Ettrick</city>
        <state>Virginia</state>
        <zip>23803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Family Practice</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry D Stonesifer, MD Inc., PS</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clínicas de Bahía Blanca</name>
      <address>
        <city>Bahía Blanca</city>
        <zip>B8000FTD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIPREC</name>
      <address>
        <city>Caba</city>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENUDIAB</name>
      <address>
        <city>Caba</city>
        <zip>C1440AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Especializado</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Asociados de Endocrinología e Invest Clínica</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPAC - Clínica Privada Caraffa SRL</name>
      <address>
        <city>Cordoba</city>
        <zip>X5008KKF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Corrientes Juana Francisca Cabra</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400AMZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ilaim-Ceom</name>
      <address>
        <city>Córdoba</city>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de La Plata</name>
      <address>
        <city>La Plata</city>
        <zip>B1900AWT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIPADI</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500EVJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas de Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>S2000CVD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Hematología y Medicina Clínica Dr. Rubén Davoli</name>
      <address>
        <city>Rosario</city>
        <zip>S2000CXP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Bernardo</name>
      <address>
        <city>Salta</city>
        <zip>A4406CLA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clinicas Tucuman</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>T4000ICL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Biomédicas</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FNF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clínicas del Litoral</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000SWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital-Endocrinology</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Logan Hospital</name>
      <address>
        <city>Meadowbrook</city>
        <state>Queensland</state>
        <zip>4131</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Clinical Research Unit</name>
      <address>
        <city>East Ringwood</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blankenberge - PRAC Vileyn, Geert</name>
      <address>
        <city>Blankenberge</city>
        <zip>8370</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bonheiden - HOSP Imelda</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De Pinte - PRAC Hollanders, Geert</name>
      <address>
        <city>De Pinte</city>
        <zip>9840</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retie - PRAC De Vos, Axel</name>
      <address>
        <city>Dessel</city>
        <zip>2480</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deurne - PRAC Heyvaert, Frank</name>
      <address>
        <city>Deurne</city>
        <zip>2100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deurne - PRAC Verelst, Joost</name>
      <address>
        <city>Deurne</city>
        <zip>2100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genk - PRAC Vernijns, J.</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gozée - PRAC De Meulemeester, Marc</name>
      <address>
        <city>Gozée</city>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasselt - PRAC Vantroyen, Daniel</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herent - PRAC Denolf, Bart</name>
      <address>
        <city>Herent</city>
        <zip>3020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkebeek - PRAC Maury, Olivier</name>
      <address>
        <city>Linkebeek</city>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorsel - PRAC Van Mulders, N.</name>
      <address>
        <city>Moorsel</city>
        <zip>9310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natoye - PRAC Balthazar, Y.</name>
      <address>
        <city>Natoye</city>
        <zip>5360</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tremelo - PRAC Vermeersch, Lode</name>
      <address>
        <city>Tremelo</city>
        <zip>3210</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário João de Barros Barreto</name>
      <address>
        <city>Belém</city>
        <zip>66073-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Paraná</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Goiânia Alberto Rassi</name>
      <address>
        <city>Goiânia</city>
        <zip>74043-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas Ltda</name>
      <address>
        <city>Higienópolis</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Diabetes e Hipertensão</name>
      <address>
        <city>Joaquim Távora</city>
        <zip>60115-282</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas em Diabetes</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Diabetes e Endocrinologia</name>
      <address>
        <city>Río de Janeiro</city>
        <zip>20211-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo - IPEC - Instituto de Pesquisa Clínica</name>
      <address>
        <city>Santa Cecília</city>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Molestias Cardiovasculares - IMC</name>
      <address>
        <city>São José do Rio Preto</city>
        <zip>15015-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Rim e Hipertensão - UNIFESP</name>
      <address>
        <city>Vila Clementino</city>
        <zip>04025-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.Multiprofile Hospital &quot;Dr. Georgy Stranski&quot; EAD, Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Zaritza Johanna&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Clin. Endocrinology &amp; Metab. Dis.</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Prof Stoyan Kirkovich AD</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCPQ (Laval University)</name>
      <address>
        <city>Quebec</city>
        <state>Migration Data</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Line Medical Services Ltd.</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Topsail Road Medical Clinic</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Cardiac Care Inc.</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Incorporated</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilderman Medical Clinic</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albion Finch Medical Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings County Medical Centre</name>
      <address>
        <city>Montague</city>
        <state>Prince Edward Island</state>
        <zip>C0A 1R0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dynamik Research</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulta Privada Maria Loreto Aguirre Coveña</name>
      <address>
        <city>Providencia</city>
        <zip>7500010</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Servicios Médicos Godoy Ltda</name>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Antulawen</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Naval Almirante Nef</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioMelab</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cientifico Asistencial Jose Luis Accini</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion del Caribe de Investigacion Biomedica</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocare Research Institute</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dexa Diabetes Servicios Médicos Ltda</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIENDO Unidad Integral de Endocrinologia</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro cardiovascular Aristides</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centro de Diagnostico Cardiologico para la Investigacion Bio</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiovascular de Colombia</name>
      <address>
        <city>El Bosque</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Oftalmologica de Santander</name>
      <address>
        <city>El Bosque</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Centro de Investigaciones Biomédicas Riescard</name>
      <address>
        <city>Tolima</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal &amp; Diabetology Ambulance, Jablonec nad Nisou</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <zip>466 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetology &amp; Internal Ambulance</name>
      <address>
        <city>Olomouc-Lazce</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal &amp; Diabetology Ambulance Dr. Vrkoc, Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology ambulance, Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ResTrial s.r.o.</name>
      <address>
        <city>Praha 8</city>
        <zip>181 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diebetology internal Ambulance</name>
      <address>
        <city>Praha</city>
        <zip>101 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal &amp; Diabetology Ambulance, Prostejov</name>
      <address>
        <city>Prostejov</city>
        <zip>796 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Strakonice, Internal Department</name>
      <address>
        <city>Strakonice</city>
        <zip>386 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetesklinikka, Mehiläinen Töölö</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lääkärikeskus Ite</name>
      <address>
        <city>Joensuu</city>
        <zip>80100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lääkärikeskus Aava Kerava</name>
      <address>
        <city>Kerava</city>
        <zip>04200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkolan Lääkärikeskus</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IteLasaretti</name>
      <address>
        <city>Kuopio</city>
        <zip>FI-70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Oulu, Diapolis</name>
      <address>
        <city>Oulu</city>
        <zip>FI-90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Hell M, MG, Behren Les Forbach</name>
      <address>
        <city>Behren Les Forbach</city>
        <zip>57460</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Haut Levèque, Diabéto, Pessac</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Lemarie B, MG, Bourg des Cptes</name>
      <address>
        <city>Bourg des Comptes</city>
        <zip>35890</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Cadinot Dr D, Broglie</name>
      <address>
        <city>Broglie</city>
        <zip>27270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Breton Dr Nicolas</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Ferrier R, MG, Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Jordan E, MG, Carbonne</name>
      <address>
        <city>Carbonne</city>
        <zip>31390</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Merlin P, MG Castets</name>
      <address>
        <city>Castets</city>
        <zip>40260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Fonteny R, MG, Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Fournier P, MG, Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Martocq G, MG, Cournonterral</name>
      <address>
        <city>Cournonterral</city>
        <zip>34660</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP, Fort de France, Fort de France</name>
      <address>
        <city>Fort De France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Le Mouel S, MG, Hinx</name>
      <address>
        <city>Hinx</city>
        <zip>40180</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Pholsena, MG, La Réunion</name>
      <address>
        <city>La Reunion</city>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Bismuth M</name>
      <address>
        <city>Labarthe sur Leze</city>
        <zip>31860</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Zimmermann D</name>
      <address>
        <city>Louvigne De Bie</city>
        <zip>35680</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Mainetti P, MG, Maintenon</name>
      <address>
        <city>Maintenon</city>
        <zip>28130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Barucq F, MG, Orthez</name>
      <address>
        <city>Orthez</city>
        <zip>64300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Mostephai M</name>
      <address>
        <city>Orthez</city>
        <zip>64300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Cassagnes JL, MG, Palau Del Vidre</name>
      <address>
        <city>Palau Del Vidre</city>
        <zip>66690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Mercey Y, MG, St Genies des Fontaines</name>
      <address>
        <city>Saint Genies Des Fontaines</city>
        <zip>66740</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hop St Dié des Vosges, Diabéto, St Dié des Vosges</name>
      <address>
        <city>St Dié des Vosges Cedex</city>
        <zip>88187</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Bonneau D, MG, Thouars</name>
      <address>
        <city>Thouars</city>
        <zip>79100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Morel H, MG, Tilly sur Seulles</name>
      <address>
        <city>Tilly sur Seulles</city>
        <zip>14250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Ajara LLC, Private Practice</name>
      <address>
        <city>Batumi</city>
        <zip>6004</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital LTD 'Gormedi', Gori</name>
      <address>
        <city>Gori</city>
        <zip>1400</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L&amp;J Clinic, Kutaisi</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EC Cardiology Clinic,Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Diabetes Research Ltd., Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Endocrinology, Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhordania Institute of Human Reproduction, Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Medelite Ltd., Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chemotherapy &amp; Immunotherapy Clinic 'Medulla', Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC 'Curatio'</name>
      <address>
        <city>Zugdidi</city>
        <zip>2100</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, AöR</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Klausmann</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis, Asslar</name>
      <address>
        <city>Asslar</city>
        <zip>35614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Naumburger, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10409</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Rieker, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IFG Institut für Gesundheitsförderung GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12621</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ DaVita Dormagen GmbH</name>
      <address>
        <city>Dormagen- Hackenbroich</city>
        <zip>41540</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Busch, Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schlecht, Eisenach</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZKS Südbrandenburg GmbH</name>
      <address>
        <city>Elsterwerda</city>
        <zip>04910</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Huptas, Essen</name>
      <address>
        <city>Essen</city>
        <zip>45307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schmidt, Flörsheim</name>
      <address>
        <city>Flörsheim</city>
        <zip>65439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Stoffwechselforschung, Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60322</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Groeneveld, Furth im Wald</name>
      <address>
        <city>Furth im Wald</city>
        <zip>93437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kohlhas, Gebhardshain</name>
      <address>
        <city>Gebhardshain</city>
        <zip>57580</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Samer, Haag</name>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Management &amp; Services GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Burkhardt, Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabeteszentrum Alstertal, Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Herrmann, Hatten</name>
      <address>
        <city>Kirchhatten</city>
        <zip>26209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dünnwaldpraxis, Köln</name>
      <address>
        <city>Köln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klein, Künzing</name>
      <address>
        <city>Künzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Nischik, Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kropp, Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23554</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PFÜTZNER Science &amp; Health Institute GmbH</name>
      <address>
        <city>Mainz</city>
        <zip>55128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Münster</city>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Böckmann</name>
      <address>
        <city>Neumünster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Hilgenberg</name>
      <address>
        <city>Rehburg-Loccum</city>
        <zip>31547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Naudts, Rodgau</name>
      <address>
        <city>Rodgau/Dudenhofen</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Hirschhäuser</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Segner, St. Ingberg</name>
      <address>
        <city>Saint Ingbert / Oberwürzbach</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Herrmann</name>
      <address>
        <city>Schwabenheim</city>
        <zip>55270</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Dietlein</name>
      <address>
        <city>Stadtbergen</city>
        <zip>86391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Sauter</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Diabetologie</name>
      <address>
        <city>Zwenkau</city>
        <zip>04442</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Evangelismos</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital &quot;Attikon&quot;</name>
      <address>
        <city>Haidari, Athens</city>
        <zip>12410</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Gen. Hosp. of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Amalia Fleming&quot;</name>
      <address>
        <city>Melissia, Athens</city>
        <zip>15127</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Nikaia</name>
      <address>
        <city>Nikaia</city>
        <zip>18484</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hopsital of Thessaloniki &quot;Ippokrateio&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniki Thermi</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imre Magyar Hospital, Ajka</name>
      <address>
        <city>Ajka</city>
        <zip>8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lausmed Kft. Outpatient Unit of Internal Medicine</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolyi Sandor Hospital, Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1041</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes County Pandy Kalman Hospital</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erzsebet Hospital, Hodmezövasarhely</name>
      <address>
        <city>Hódmezövásárhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Samuel Diosszilagyi Hospital and Outpatient Clinic, Mako</name>
      <address>
        <city>Mako</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TaNa Med Kft.</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grof Esterhazy Hospital and Outpatient Clinic</name>
      <address>
        <city>Papa</city>
        <zip>8500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolna County Balassa Janos Hospital</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Krishna Hospital and Heart Care Centre, Ahmedabad</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIIGMA Institute of Medical Sciences Pvt Ltd</name>
      <address>
        <city>Aurangabad</city>
        <zip>431001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Ramaiah Memorial Hospital,</name>
      <address>
        <city>Bangalore, Karnataka</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes care and research centre</name>
      <address>
        <city>Bangalore</city>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Diabetes Centre (BDC)- Medisys Clinical Research</name>
      <address>
        <city>Bangalore</city>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgaum Diabetes Centre, Belgaum</name>
      <address>
        <city>Belgaum</city>
        <zip>590001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swamy Diabetes Centre</name>
      <address>
        <city>Chennai</city>
        <zip>600 028</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Chennai</city>
        <zip>600010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M V Hospital For Diabetes and Diabetes Research Centre</name>
      <address>
        <city>Chennai</city>
        <zip>600013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Mohans Diabetes Speciality Centre</name>
      <address>
        <city>Chennai</city>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kovai Diabetes Speciality Centre &amp; Hospital</name>
      <address>
        <city>Coimbatore</city>
        <zip>641009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TOTALL Diabetes Hormone Institute</name>
      <address>
        <city>Indore</city>
        <zip>452010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Thyroid and Endocrine Centre</name>
      <address>
        <city>Jaipur</city>
        <zip>302 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamed Clinical Research Services Pvt. Ltd.</name>
      <address>
        <city>Jaipur</city>
        <zip>302016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Foundation, Ruby Hall Clinic</name>
      <address>
        <city>Maharashtra</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K.G.N. Diabetes and Endocrine Centre</name>
      <address>
        <city>Mumbai, Maharastra</city>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Hospital- Superspeciality &amp; Transplant Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHIDEM</name>
      <address>
        <city>Mumbai</city>
        <zip>400014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunil's Diabetes care and Research Centre</name>
      <address>
        <city>Nagpur</city>
        <zip>440 010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahingir Clinical Development Centre</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deshmukh Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Care Center</name>
      <address>
        <city>Thiruvananthapuram</city>
        <zip>695 010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yalamanchi Hospitals &amp; Research Centres Pvt Ltd.</name>
      <address>
        <city>Vijayawada</city>
        <zip>520 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Red House Family Practice</name>
      <address>
        <city>Co. Cork</city>
        <zip>CORK</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connolly Hospital Blanchardstown</name>
      <address>
        <city>Dublin</city>
        <zip>15</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Palms GP Surgery</name>
      <address>
        <city>Gorey</city>
        <zip>Wexford</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fethard-on-Sea Medical Practice</name>
      <address>
        <city>Wexford</city>
        <zip>Wexford</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center, Diabetic Unit, Holon</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center, Ein-Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center Tel Hashomer</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;SS. Trinità&quot;</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Mater Domini, Universita di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Guastalla</name>
      <address>
        <city>Guastalla (RE)</city>
        <zip>42016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.Policlinico G.Martino</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Pertini</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Gruppo Multimedica</name>
      <address>
        <city>Sesto San Giovanni (MI)</city>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daishinkai Medical Corporation Ookuma Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <zip>462-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chibanishi General Hospital</name>
      <address>
        <city>Chiba, Matsudo</city>
        <zip>270-2251</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Tokyo Heart Clinic</name>
      <address>
        <city>Chiba, Matsudo</city>
        <zip>271-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kashinoki I.M. Clinic, Fukushima, I.M.</name>
      <address>
        <city>Fukushima, Date</city>
        <zip>960-0418</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Nihonmatsu Hospital</name>
      <address>
        <city>Fukushima, Nihonmatsu</city>
        <zip>964-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwase General Hospital</name>
      <address>
        <city>Fukushima, Sukagawa</city>
        <zip>962-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iryohojinshadan Sasaki Clinic</name>
      <address>
        <city>Hyogo, Amagasaki</city>
        <zip>660-0827</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takasagoseibu Hospital</name>
      <address>
        <city>Hyogo, Takasago</city>
        <zip>676-0812</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Clinic Diabetes Care Center</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Rosai Hospital</name>
      <address>
        <city>Kumamoto, Yatsushiro</city>
        <zip>866-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koga General Hospital</name>
      <address>
        <city>Miyazaki, Miyazaki</city>
        <zip>880-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Cooperative Association Hanyu General Hospital</name>
      <address>
        <city>Saitama, Hanyu</city>
        <zip>348-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo, Itabashi-ku</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National Univ. Hosp</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hosp</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Johor Bahru, Johor</city>
        <zip>80100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University Sains Malaysia</name>
      <address>
        <city>Kota Bharu</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tengku Ampuan Afzan</name>
      <address>
        <city>Kuantan</city>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Melaka</name>
      <address>
        <city>Melaka</city>
        <zip>75400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penang Medical College</name>
      <address>
        <city>Penang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Taiping</name>
      <address>
        <city>Taiping</city>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Acapulco</name>
      <address>
        <city>Acapulco</city>
        <zip>39570</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Cardiometabolica de Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20234</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Ignacio Chavez</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion Clinica Cardiometabolica de Occident</name>
      <address>
        <city>Guadalajara</city>
        <zip>44150</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huisartspraktijk Emmers</name>
      <address>
        <city>'s-hertogenbosch</city>
        <zip>5235 KG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FlevoResearch</name>
      <address>
        <city>Almere</city>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis Beverwijk</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Breda</name>
      <address>
        <city>Breda</city>
        <zip>4811 SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep, location Den Helder</name>
      <address>
        <city>Den Helder</city>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5611 NV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Noord</name>
      <address>
        <city>Groningen</city>
        <zip>9711 SG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasculair Onderzoek Centrum</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3039 BD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotterdam Research Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3039 BD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Oost</name>
      <address>
        <city>Velp</city>
        <zip>6883 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Leiden-Zoetermeer</name>
      <address>
        <city>Zoetermeer</city>
        <zip>2724 EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RMC Medical Research Ltd</name>
      <address>
        <city>Dunedin</city>
        <zip>9012</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research, Wellington</name>
      <address>
        <city>Newtown Wellington NZ</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research, Promed House</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodø Legesenter AS, avd. for med. studier</name>
      <address>
        <city>Bodø</city>
        <zip>N-8001</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi 3 Innlandet AS, avd Elverum</name>
      <address>
        <city>Elverum</city>
        <zip>N-2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF, Bærum sykehus</name>
      <address>
        <city>Gjettum</city>
        <zip>N-1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Helse AS</name>
      <address>
        <city>Hamar</city>
        <zip>N-2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bylegene SA</name>
      <address>
        <city>Jessheim</city>
        <zip>N-2050</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heiaklinikken</name>
      <address>
        <city>Lierskogen</city>
        <zip>N-3420</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rådhuset Spesialistsenter</name>
      <address>
        <city>Oslo</city>
        <zip>N-0160</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandvika Spesialistsenter</name>
      <address>
        <city>Sandvika</city>
        <zip>N-1337</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grålum Legesenter</name>
      <address>
        <city>Sarpsborg</city>
        <zip>N-1727</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forusakutten - Kolibri Medical, Avd. Stavanger</name>
      <address>
        <city>Stavanger</city>
        <zip>N-4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi 3 AS</name>
      <address>
        <city>Ålesund</city>
        <zip>N-6002</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Delgado de Investigacion Medica</name>
      <address>
        <city>Arequipa</city>
        <zip>LIMA 54</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica San Pedro</name>
      <address>
        <city>Huacho</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Dos de Mayo</name>
      <address>
        <city>Lima</city>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas METABOLICARE SAC</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica San Gabriel</name>
      <address>
        <city>Lima</city>
        <zip>Lima 32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Especialidades Medicas Santa Maria S.A.C</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica San Judas Tadeo</name>
      <address>
        <city>San Miguel</city>
        <zip>32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Diabetes Care</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Mediatrix Medical Center</name>
      <address>
        <city>Lipa City, Batangas</city>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manila Doctors Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1011</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Hospital &amp; Medical Center</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quirino Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Santos Medical Center</name>
      <address>
        <city>San Juan</city>
        <zip>1503</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surigao Health Specialists</name>
      <address>
        <city>Surigao</city>
        <zip>8400</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fernando Fonseca, EPE</name>
      <address>
        <city>Amadora</city>
        <zip>2700-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLO, EPE - Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUC - Centro Hospitalar e Universitário de Coimbra, EPE</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar da Cova da Beira Hospital Pêro da Covilhã</name>
      <address>
        <city>Covilhã</city>
        <zip>6200-251</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital Figueira da Foz, EPE</name>
      <address>
        <city>Figueira da Foz</city>
        <zip>3094-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar São João,EPE</name>
      <address>
        <city>Porto</city>
        <zip>4202-451</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião</name>
      <address>
        <city>Santa Maria da Feira</city>
        <zip>4520-211</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Diabol SRL, Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicodiab SRL, Bucharest</name>
      <address>
        <city>Bucharest</city>
        <zip>010507</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Medical Centre &quot;Sanatatea Ta&quot; SRL, Bucharest</name>
      <address>
        <city>Bucharest</city>
        <zip>020614</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultmed SRL, Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700547</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Clinical Hospital, Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Dr. Remus Gagiu</name>
      <address>
        <city>Tirgoviste</city>
        <zip>130083</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Clinic of new technologies of medicine</name>
      <address>
        <city>Dzerzhinsky</city>
        <zip>140091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 6 of MoH of Udmurt Republic</name>
      <address>
        <city>Izhevsk</city>
        <zip>436000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 4, Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 13, Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Central Clinical Hospital of RAS&quot;, Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>117333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 61, Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>119048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution, Regional hospital #2</name>
      <address>
        <city>Rostov-na-Donu</city>
        <zip>344029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;CENTER DIABET&quot;, Samara</name>
      <address>
        <city>Samara</city>
        <zip>443067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MMU City Outpatient Clinic no. 20, Saratov</name>
      <address>
        <city>Saratov</city>
        <zip>410018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Center Zvezdara, Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Pancevo</name>
      <address>
        <city>Pancevo</city>
        <zip>26000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Subotica, Internal Medicine</name>
      <address>
        <city>Subotica</city>
        <zip>24000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Zemun</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIASTYLE s.r.o., Diabetology Outpatient Department</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENDIAMED s.r.o., Dolny Kubin</name>
      <address>
        <city>Dolny Kubin</city>
        <zip>026 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CELL B s.r.o.</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIA-KONTROL s.r.o.</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Funkystuff s.r.o., Nove Zamky</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologicka ambulancia MUDr. Lucia Gajdosikova s.r.o.</name>
      <address>
        <city>Povazska Bystrica</city>
        <zip>017 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDIVASA s.r.o., Outpatient Clinic, Zilina</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. P. Patel</name>
      <address>
        <city>Cape Town</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. E. L. Janari</name>
      <address>
        <city>Cape Town</city>
        <zip>7965</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Vawda</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parklands Medical Centre</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jurgens</name>
      <address>
        <city>Krugersdorp</city>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Makan</name>
      <address>
        <city>Lenasia</city>
        <zip>1827</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. D. R. Lakha, Johannesburg</name>
      <address>
        <city>Lenasia</city>
        <zip>2033</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenacres Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. M. Seeber</name>
      <address>
        <city>Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vergelegen Medi-Clinic</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.A.P. Sardenya</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Les Corts</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Casanova</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Burjassot 1</name>
      <address>
        <city>Burjassot</city>
        <zip>46100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Natahoyo</name>
      <address>
        <city>Gijon</city>
        <zip>33212</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Florida</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP La Roca</name>
      <address>
        <city>La Roca Del Vallés (Barcelona)</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. El Cristo</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Colloto</name>
      <address>
        <city>Oviedo</city>
        <zip>33010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Vallobin-La Florida</name>
      <address>
        <city>Oviedo</city>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABS Pineda de Mar</name>
      <address>
        <city>Pineda de Mar</city>
        <zip>08397</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de l'Esperit Sant</name>
      <address>
        <city>Santa Coloma De Gramanet</city>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Tàrrega</name>
      <address>
        <city>Tàrrega</city>
        <zip>25300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Ingeniero Joaquin Benlloch</name>
      <address>
        <city>Valencia</city>
        <zip>46006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjukhuset, Härnösand</name>
      <address>
        <city>Härnösand</city>
        <zip>87182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avonova Hälsa AB</name>
      <address>
        <city>Järfälla</city>
        <zip>177 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes universitetssjukhus, Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalecarlia Clinical Research Center</name>
      <address>
        <city>Rättvik</city>
        <zip>795 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södra Dalarnas vårdcentral, Hedemora</name>
      <address>
        <city>Rättvik</city>
        <zip>79530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Näsets Läkargrupp</name>
      <address>
        <city>Skanör</city>
        <zip>239 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vårdcentralen Silentzvägen</name>
      <address>
        <city>Uddevalla</city>
        <zip>451 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S3 Clinical Research Centers</name>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeine Medizin</name>
      <address>
        <city>Basel</city>
        <zip>4057</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMH endocrinologia diabetologia</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Pietro Gerber</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Hua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung,</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCKUH</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shih-Kong Wu Ho-Shu Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipe Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Tien Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>23137</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>25160</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Fattouma Bourguiba, Mint, Monastir</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Hédi Chaker, Endo, Sfax</name>
      <address>
        <city>Sfax</city>
        <zip>3029</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Farhat Hached, Mint, Sousse</name>
      <address>
        <city>Sousse</city>
        <zip>4000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Habib Thameur, Mint, Tunis</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Clinical Hosp, Therapy Department</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk City Central Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 17, Kharkov</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 27, Kharkiv</name>
      <address>
        <city>Kharkov</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Cardiology &quot;Sertse i sudyny&quot;, Kiev</name>
      <address>
        <city>Kiev</city>
        <zip>01032</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 1, Kiev</name>
      <address>
        <city>Kiev</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika #2, Kyiv</name>
      <address>
        <city>Kyiv</city>
        <zip>02002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital No. 5, Lvov</name>
      <address>
        <city>Lvov</city>
        <zip>73013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odeska zaliznichna likarnya, Odessa</name>
      <address>
        <city>Odesa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsia Regional Endocrinology Dispensary</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crouch Oak Family Practice</name>
      <address>
        <city>Addlestone</city>
        <zip>KT15 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ash Vale Health Centre, Aldershot</name>
      <address>
        <city>Ash Vale, Aldershot</city>
        <zip>GU12 5BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hathaway Medical Centre</name>
      <address>
        <city>Chippenham</city>
        <zip>SN14 6GT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Surgery</name>
      <address>
        <city>Ely</city>
        <zip>CB7 4HF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospital</name>
      <address>
        <city>Great Yarmouth</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Tunisia</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <results_first_submitted>August 21, 2019</results_first_submitted>
  <results_first_submitted_qc>December 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2020</results_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT01243424/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT01243424/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicentre, multinational, randomised, double-blind, double-dummy, parallel group,comparator-controlled trial compared Linagliptin versus (vs.) Glimepiride, predominantly on metformin background treatment in participants with type 2 diabetes mellitus (T2DM) at elevated cardiovascular (CV) risk receiving usual care.</recruitment_details>
      <pre_assignment_details>All participants were screened for eligibility to participate in the trial. Participants attended specialist sites which would then ensure that all participants met all inclusion/exclusion criteria. Participants were not to be randomised to trial treatment if any one of the specific entry criteria were not met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin</title>
          <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Glimepiride</title>
          <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Discontinuation From Study (Treated Set)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3028"/>
                <participants group_id="P2" count="3014"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patient Died (Other Cause Than CV Death)</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="3023"/>
                <participants group_id="P2" count="3010"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2899"/>
                <participants group_id="P2" count="2895"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent Withdrawn (Status Alive)</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn (Status Unknown)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closure (Status Alive)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closure (Status Unknown)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>LostToFollowUpfor3P−MACE(StatusAlive)</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>LostToFollowUpfor3P−MACE(StatusUnknown)</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Discontinuation From Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3028"/>
                <participants group_id="P2" count="3014"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="3023"/>
                <participants group_id="P2" count="3010"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1896"/>
                <participants group_id="P2" count="1832"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1132"/>
                <participants group_id="P2" count="1182"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="457"/>
                <participants group_id="P2" count="523"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="328"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than listed above</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): All patients treated with at least one dose of trial drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin</title>
          <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Glimepiride</title>
          <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3023"/>
            <count group_id="B2" value="3010"/>
            <count group_id="B3" value="6033"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="9.5"/>
                    <measurement group_id="B2" value="64.2" spread="9.5"/>
                    <measurement group_id="B3" value="64.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1185"/>
                    <measurement group_id="B2" value="1229"/>
                    <measurement group_id="B3" value="2414"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1838"/>
                    <measurement group_id="B2" value="1781"/>
                    <measurement group_id="B3" value="3619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="519"/>
                    <measurement group_id="B2" value="513"/>
                    <measurement group_id="B3" value="1032"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2495"/>
                    <measurement group_id="B2" value="2487"/>
                    <measurement group_id="B3" value="4982"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="531"/>
                    <measurement group_id="B2" value="530"/>
                    <measurement group_id="B3" value="1061"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2217"/>
                    <measurement group_id="B2" value="2190"/>
                    <measurement group_id="B3" value="4407"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The First 3-point Major Adverse Cardiovascular Events (3P−MACE)</title>
        <description>The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.</description>
        <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
        <population>Treated set (TS): All patients treated with at least one dose of trial drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The First 3-point Major Adverse Cardiovascular Events (3P−MACE)</title>
          <description>The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.</description>
          <population>Treated set (TS): All patients treated with at least one dose of trial drug.</population>
          <units>Events/ 1000 patients-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3023"/>
                <count group_id="O2" value="3010"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This was the first step in a pre-defined hierarchical testing approach. The upper bound of the confidence interval (CI) of the Hazard ratio (HR) of linagliptin vs. glimepiride was compared with this noninferiority margin for the testing of non-inferiority. All non-inferiority tests were based on a margin of 1.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values derived from Wald´s Chi-square test for non-inferiority were calculated.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional-hazard model with factor treatment was applied to compare linagliptin with glimepiride</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95.47</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was the second step in a pre-defined hierarchical testing approach.</non_inferiority_desc>
            <p_value>0.3813</p_value>
            <p_value_desc>P-values derived from Wald´s Chi-square test.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional-hazard model with factor treatment was applied to compare linagliptin with glimepiride.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95.47</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The First 4-point (4P)− MACE</title>
        <description>The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.</description>
        <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The First 4-point (4P)− MACE</title>
          <description>The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.</description>
          <population>TS</population>
          <units>Events/ 1000 patients-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3023"/>
                <count group_id="O2" value="3010"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This was the third step in a pre-defined hierarchical testing approach.</non_inferiority_desc>
            <p_value>0.4334</p_value>
            <p_value_desc>P-values derived from Wald´s Chi-square test for non-inferiority.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional-hazard model with factor treatment was applied to compare linagliptin with glimepiride.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95.47</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without &gt;2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase</title>
        <description>The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without &gt;2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.</description>
        <time_frame>From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)</time_frame>
        <population>TS without duplicates (TS w/o duplicates), patients who are off-drug or died prior to regular study stop were handled as non-completers considered failure (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without &gt;2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase</title>
          <description>The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without &gt;2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.</description>
          <population>TS without duplicates (TS w/o duplicates), patients who are off-drug or died prior to regular study stop were handled as non-completers considered failure (NCF).</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3014"/>
                <count group_id="O2" value="3000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="14.7" upper_limit="17.3"/>
                    <measurement group_id="O2" value="10.2" lower_limit="9.1" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p−value derived from logistic regression.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95.47</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
            <estimate_desc>Odds ratio and confidence interval are based on logistic regression with factor for treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without &gt;2% Weight Gain During Maintenance Phase</title>
        <description>The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without &gt;2% weight gain during maintenance phase.</description>
        <time_frame>From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)</time_frame>
        <population>TS w/o duplicates (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without &gt;2% Weight Gain During Maintenance Phase</title>
          <description>The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without &gt;2% weight gain during maintenance phase.</description>
          <population>TS w/o duplicates (NCF)</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3014"/>
                <count group_id="O2" value="3000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="16.1" upper_limit="18.8"/>
                    <measurement group_id="O2" value="14.1" lower_limit="12.9" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>p−value derived from logistic regression.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95.47</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Odds ratio and confidence interval are based on logistic regression with factor for treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE</title>
        <description>Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.</description>
        <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE</title>
          <description>Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.</description>
          <population>TS</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3023"/>
                <count group_id="O2" value="3010"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="10.7" upper_limit="13.0"/>
                    <measurement group_id="O2" value="12.0" lower_limit="10.9" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE</title>
        <description>Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.</description>
        <time_frame>From randomization until individual day of trial completion, up to 432 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE</title>
          <description>Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.</description>
          <population>TS</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3023"/>
                <count group_id="O2" value="3010"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="12.0" upper_limit="14.4"/>
                    <measurement group_id="O2" value="13.3" lower_limit="12.2" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events</title>
        <description>Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:
CV death (including fatal stroke and fatal MI)
non-fatal MI
non-fatal stroke
hospitalisation for unstable angina pectoris
TIA
hospitalisation for heart failure
hospitalisation for coronary revascularisation procedures (CABG, PCI)</description>
        <time_frame>From start of the treatment until 7 days after the end of treatment, up to 433 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events</title>
          <description>Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:
CV death (including fatal stroke and fatal MI)
non-fatal MI
non-fatal stroke
hospitalisation for unstable angina pectoris
TIA
hospitalisation for heart failure
hospitalisation for coronary revascularisation procedures (CABG, PCI)</description>
          <population>TS</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3023"/>
                <count group_id="O2" value="3010"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="15.8" upper_limit="18.5"/>
                    <measurement group_id="O2" value="17.8" lower_limit="16.4" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events</title>
        <description>Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:
CV death (including fatal stroke and fatal MI)
non-fatal MI
non-fatal stroke
hospitalisation for unstable angina pectoris
Transient ischaemic attack (TIA)
hospitalisation for heart failure
hospitalisation for coronary revascularisation procedures (CABG, PCI)</description>
        <time_frame>From start of the treatment until 7 days after the end of treatment, up to 433 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events</title>
          <description>Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:
CV death (including fatal stroke and fatal MI)
non-fatal MI
non-fatal stroke
hospitalisation for unstable angina pectoris
Transient ischaemic attack (TIA)
hospitalisation for heart failure
hospitalisation for coronary revascularisation procedures (CABG, PCI)</description>
          <population>TS</population>
          <units>Events/ 1000 patients-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3023"/>
                <count group_id="O2" value="3010"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5249</p_value>
            <p_value_desc>p−value derived from Wald´s chi−square test.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Hazard ratio and confidence interval derived from Cox regression with factor treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)</title>
        <description>Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates considering all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)</title>
          <description>Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates considering all available data</population>
          <units>Percentage glycosylated hemoglobin (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2951"/>
                <count group_id="O2" value="2949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.02"/>
                    <measurement group_id="O2" value="0.15" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>ANCOVA</method>
            <method_desc>The Analysis of Covariance (ANCOVA) model includes the fixed categorical effect of treatment and the continuous covariate of baseline HbA1c.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)</title>
        <description>Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates considering all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)</title>
          <description>Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates considering all available data</population>
          <units>Milligram/ deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2996"/>
                <count group_id="O2" value="2949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="0.9"/>
                    <measurement group_id="O2" value="19.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline FPG.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>-4.8</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol</title>
        <description>Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates, participants on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol</title>
          <description>Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates, participants on treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3014"/>
                <count group_id="O2" value="3000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2688"/>
                    <count group_id="O2" value="2660"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="0.6"/>
                    <measurement group_id="O2" value="-6.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2783"/>
                    <count group_id="O2" value="2751"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2788"/>
                    <count group_id="O2" value="2762"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="0.7"/>
                    <measurement group_id="O2" value="-0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL cholesterol, this was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6400</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline LDL cholesterol.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95.47</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL cholesterol, this was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0497</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline HDL cholesterol.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total cholesterol, this was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6823</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline total cholesterol.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Triglycerides</title>
        <description>Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates, participants on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit in Triglycerides</title>
          <description>Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates, participants on treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2788"/>
                <count group_id="O2" value="2762"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.2"/>
                    <measurement group_id="O2" value="5.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2678</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline FPG.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Creatinine</title>
        <description>Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates, participants on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit in Creatinine</title>
          <description>Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates, participants on treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2917"/>
                <count group_id="O2" value="2898"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.01"/>
                    <measurement group_id="O2" value="0.09" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5165</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline creatinine.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates, participants on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates, participants on treatment</population>
          <units>mL/minute/1.73 meter^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2917"/>
                <count group_id="O2" value="2898"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="0.3"/>
                    <measurement group_id="O2" value="-5.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5165</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline eGFR.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>Mean difference = Linagliptin mean – Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)</title>
        <description>Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates, participants on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)</title>
          <description>Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.</description>
          <population>TS w/o duplicates, participants on treatment</population>
          <units>mg/ gcrea</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2904"/>
                <count group_id="O2" value="2880"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.83"/>
                    <measurement group_id="O2" value="1.57" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2921</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effect of treatment and the continuous covariate of baseline UACR.</method_desc>
            <param_type>geometric mean (gMean) ratio (%)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>gMean ration= Linagliptin mean/ Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Transition in Albuminuria Classes</title>
        <description>Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.</description>
        <time_frame>Baseline and week 432</time_frame>
        <population>TS w/o duplicates, participants on treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Transition in Albuminuria Classes</title>
          <description>Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.</description>
          <population>TS w/o duplicates, participants on treatment</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3014"/>
                <count group_id="O2" value="3000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Base (&lt;30mg/gcrea) LVOT (&lt;30mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4"/>
                    <measurement group_id="O2" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base(&lt;30mg/gcrea)LVOT(&gt;=30 to&lt;=300mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base (&lt;30 mg/gcrea) LVOT (&gt;300 mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base (&gt;=30 to &lt;=300 mg/gcrea) LVOT(&lt;30mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base(&gt;=30to&lt;=300mg/gcrea)LVOT(&gt;=30to&lt;=300mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base (&gt;=30 to &lt;=300 mg/gcrea) LVOT(&gt;300 mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base (&gt;300 mg/gcrea) LVOT (&lt;30 mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base (&gt;300 mg/gcrea) LVOT(&gt;=30 to&lt;=300mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base (&gt;300 mg/gcrea) LVOT(&gt;300 mg/gcrea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks</title>
        <description>The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.</description>
        <time_frame>Baseline and week 208</time_frame>
        <population>Meal tolerance test(MTT) last observation carried forward(LOCF) set: Randomised and treated patients with one dose of study drug and signed the sub-study Informed Consent with valid baseline and on-treatment MTT. If values taken after rescue medication intake will be set to missing, last observed on-treatment value was carry forwarded.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks</title>
          <description>The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.</description>
          <population>Meal tolerance test(MTT) last observation carried forward(LOCF) set: Randomised and treated patients with one dose of study drug and signed the sub-study Informed Consent with valid baseline and on-treatment MTT. If values taken after rescue medication intake will be set to missing, last observed on-treatment value was carry forwarded.</population>
          <units>Picomol/ minute/meter^2 (pmol/min/m²)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.07" spread="15.07"/>
                    <measurement group_id="O2" value="6.95" spread="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was the fifth step in a pre-defined hierarchical testing approach.</non_inferiority_desc>
            <p_value>0.8402</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes the fixed categorical effects of treatment and the continuous covariate of baseline ISR.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.46</ci_lower_limit>
            <ci_upper_limit>44.71</ci_upper_limit>
            <estimate_desc>Mean difference= Linagliptin mean- Glimepiride mean</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up</title>
        <description>Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.</description>
        <time_frame>433 weeks</time_frame>
        <population>Full analysis set cognition(FAS-COG): Randomised and treated patients with one dose of study drug, baseline assessment (the z-scores, A&amp;E or Mini-mental state examination(MMSE) can be calculated), years of formal education with baseline MMSE≥24 and at least one on-treatment assessment (of which at least one of the RBI scores can be calculated).</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up</title>
          <description>Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.</description>
          <population>Full analysis set cognition(FAS-COG): Randomised and treated patients with one dose of study drug, baseline assessment (the z-scores, A&amp;E or Mini-mental state examination(MMSE) can be calculated), years of formal education with baseline MMSE≥24 and at least one on-treatment assessment (of which at least one of the RBI scores can be calculated).</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1618"/>
                <count group_id="O2" value="1545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="25.6" upper_limit="30.0"/>
                    <measurement group_id="O2" value="27.6" lower_limit="25.4" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This was the fifth step in a pre-defined hierarchical testing approach.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9112</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with terms for treatment as a fixed effect with Wald confidence Interval was used.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Linagliptin vs. Glimepiride odds is presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study</title>
        <description>Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.</description>
        <time_frame>Baseline</time_frame>
        <population>The sub-study was stopped early and required target with an estimated time point of 432 weeks was not achieved for this endpoint. Thus the data were not unblinded and only the baseline data collected were reported overall and not by treatment arm for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose or 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. All doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study</title>
          <description>Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.</description>
          <population>The sub-study was stopped early and required target with an estimated time point of 432 weeks was not achieved for this endpoint. Thus the data were not unblinded and only the baseline data collected were reported overall and not by treatment arm for this endpoint.</population>
          <units>Milligrams/ deciliter (mg/ dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study</title>
        <description>Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.</description>
        <time_frame>Baseline</time_frame>
        <population>The sub-study was stopped early and required target with an estimated time point of 432 weeks was not achieved for this endpoint. Thus the data were not unblinded and only the baseline data collected were reported overall and not by treatment arm for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose or 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. All doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study</title>
          <description>Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.</description>
          <population>The sub-study was stopped early and required target with an estimated time point of 432 weeks was not achieved for this endpoint. Thus the data were not unblinded and only the baseline data collected were reported overall and not by treatment arm for this endpoint.</population>
          <units>Millimoles/ Litre (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of the treatment until 7 days after the end of treatment, up to 433 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin</title>
          <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of 5 milligram (mg) linagliptin plus 1 over-encapsulated tablet of placebo matching glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Glimepiride</title>
          <description>After 2-4 weeks placebo run-in phase, participants were administered 1 tablet of placebo matching linagliptin plus 1 over-encapsulated tablet of 1 to 4 mg glimepiride, which was uptitrated in 4-week intervals during the first 16 weeks of treatment to the next dose. Both doses were administered once daily orally up to an estimated 432 weeks treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="336" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1403" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1448" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Splenic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Long QT syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thyrotoxic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomatous polyposis coli</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Choledochal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Corneal dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fibrous dysplasia of bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hereditary haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ichthyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Left ventricle outflow tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Porokeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Stargardt's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urachal abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aural polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Conductive deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ear canal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mixed deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aphakia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dry age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Endocrine ophthalmopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Eyelid rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Iris neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uveitic glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vitreous degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Appendiceal mucocoele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bezoar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colon dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dental necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastroduodenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intestinal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retroperitoneal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adhesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Implant site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retention cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholestatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gallbladder necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Actinomycotic pulmonary infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Administration site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colon gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Creutzfeldt-Jakob disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric ulcer helicobacter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Morganella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteomyelitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pyelonephritis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Septic arthritis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small intestine gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anaesthetic complication cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bone fragmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carotid artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chemical burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Conjunctival laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fracture of penis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Impacted fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Incarcerated incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Inflammation of wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Injury corneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumoconiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post procedural urine leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postoperative renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postpericardiotomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Traumatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urethral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Computerised tomogram head abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ambulatory abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Full blood count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatitis C virus test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myelocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Positron emission tomogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bone atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Limb deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Angiosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Breast cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Conjunctival melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cutaneous lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dysplastic naevus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Enchondromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ependymoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Essential thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hairy cell leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intraductal papillary mucinous neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lentigo maligna recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Malignant polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mucinous adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myxofibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neurofibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oral papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Paranasal sinus and nasal cavity malignant neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pleural sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Porocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prolactin-producing pituitary tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Refractory anaemia with ringed sideroblasts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sebaceous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skin angiosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Soft tissue sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the hypopharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transitional cell cancer of the renal pelvis and ureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tumour ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Waldenstrom's macroglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basal ganglia haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basilar artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Basilar artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Central pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Encephalomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Generalised non-convulsive epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hemianopia homonymous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertensive cerebrovascular disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Internal carotid artery kinking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intracranial mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mononeuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Paralysis recurrent laryngeal nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Quadriplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Retinal migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tunnel vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vertebral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device defective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device fastener issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Agitated depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Encopresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transient psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atonic urinary bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lower urinary tract symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Obstructive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ureteral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ureteral polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diaphragm muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pharyngeal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pulmonary toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nail bed inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Solar lentigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transient acantholytic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Umbilical haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Loss of personal independence in daily activities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Sexual abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Mitral valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Prostatic operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Atherosclerotic plaque rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Ischaemic limb pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2376" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="2504" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="365" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="340" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="530" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="517" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="313" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="319" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="318" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="312" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="422" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="483" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="1067" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="308" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="388" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="368" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="358" subjects_at_risk="3010"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="295" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="290" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="430" subjects_at_risk="3023"/>
                <counts group_id="E2" subjects_affected="452" subjects_at_risk="3010"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

